In late November, a pandemic was experienced by humanity. COVID-19 is brought on by the novel corona virus, or nCov-19. In the months of December 2019, Wuhan City, China, announced the first case. Convalescent plasma (CP) therapy is anticipated to boost the survivable rate even though there are no specific medications that have been approved for its treatment yet. Many infectious diseases have been treated and prevented by plasma therapy, a traditional adaptive immunotherapy. A viable treatment option for COVID-19 rescue may be plasma therapy. High neutralising antibody titres COVID-19 survivors may make excellent sources for plasma donations. Convalescent blood products’ potential for clinical benefit and risk in COVID-19 are still unknown. The role, advantages, and efficacy of plasma therapy are discussed in this review for the study of COVID 19 and plasma therapy.